Healthcare Stocks Gain as Investors Shift Away From AI Sector

Healthcare and pharmaceutical stocks have experienced a period of growth as investors move capital away from AI-focused technology shares, responding to concerns about volatility in the technology sector.

Recent market data shows that the S&P 500 Health Care Index increased by approximately 10% during a time when the broader S&P 500 fell by about 1.1%. This shift reflects a broader trend of investors seeking sectors with more stable earnings and lower volatility, particularly in biotechnology and pharmaceuticals.

Several major healthcare companies have recorded substantial gains. Eli Lilly's stock rose around 29% since late October, making it the first healthcare firm to reach a $1 trillion market capitalization. Other companies such as Regeneron, Merck, and Biogen each saw their share prices climb by at least 18% over the same period.

Institutional investment in healthcare has also increased. Global healthcare exchange-traded funds attracted $6.8 billion in new investments in November 2025, marking the largest monthly inflow for the sector in five years. This trend suggests a re-evaluation of the sector's prospects by large investors.

What the numbers show

• The S&P 500 Health Care Index rose about 10% while the S&P 500 fell 1.1%.
• Eli Lilly's market value reached $1 trillion after a 29% stock increase since late October.
• Healthcare ETFs attracted $6.8 billion in November 2025, the highest monthly inflow in five years.
• Healthcare sector forward P/E was near 15.6×, about 30% lower than the S&P 500's 22.8×.
• Biotech and pharma firms acquired 37 biotech companies worth at least $1 billion in 2026.

Valuation metrics indicate that healthcare stocks are trading at a substantial discount compared to the broader market. The forward price-to-earnings ratio for the healthcare sector was close to 15.6, while the S&P 500 overall stood at 22.8, representing the widest discount in decades at roughly 30%.

Investment firms have highlighted this shift. Morgan Stanley stated that as semiconductor stocks weaken, investors are likely to turn toward biotechnology shares. UBS recommended European pharmaceutical stocks, citing factors such as improving earnings, lower valuations, and lighter ownership compared to AI-linked companies.

Merger and acquisition activity has also increased in the sector. In 2026, biotech and pharma companies completed 37 acquisitions of biotech firms valued at $1 billion or more, surpassing the total number of such deals in the previous year. This activity has been supported by strong drug sales and a favorable regulatory environment.

Some investors are also moving from companies focused solely on AI to those that benefit from AI adoption in their operations. Healthcare is viewed as a sector offering opportunities for AI-related innovation with less direct correlation to technology stocks, providing a defensive yet growth-oriented investment approach.

* This article is based on publicly available information at the time of writing.